Skip Navigation

Faculty Directory

Richard E. Chaisson, MD

Director, Center for TB Research, Principal Investigator, Center for AIDS Research

Professor

Departmental Affiliation(s):

School of Medicine (Primary)
Epidemiology (Joint)
Division: Infectious Disease Epidemiology
International Health (Joint)

Center & Institute Affiliation(s):

Contact Information

1550 Orleans Street
Room 108
Baltimore , Maryland   21231
US        

410-955-1755
410-955-0740

CREATE: http://www.tbhiv-create.org/
CFAR: http://www.hopkinscfar.org

SciVal Experts Research Profile

Education

MD

Overview

Richard E. Chaisson, M.D., is Professor of Medicine, Epidemiology and International Health and Director of the Johns Hopkins University Center for Tuberculosis Research and Principal Investigator of the Hopkins Center for AIDS Research (CFAR). The Center for Tuberculosis Research is a multidisciplinary research and training center with more than $180 million in grants for the study of TB from bench to bedside.  The new CFAR is a $16 million program to promote interdisciplinary HIV research, support new investigators and address the Baltimore HIV epidemic.

Dr. Chaisson's research interests focus on tuberculosis and HIV infection, including global epidemiology and control, prevention, clinical trials, and public health interventions. He is currently principal investigator of 11 research grants, and is principal investigator of the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), an international research consortium funded by the Bill and Melinda Gates Foundation to assess the impact of novel strategies for controlling HIV-related TB. He has published over 380 scientific papers and book chapters.

Honors and Awards

World Lung Health Award, American Thoracic Society, 2006

MD Dept Health & Mental Hygiene David Glasser Award, 2008

CDC Charles C. Shepard Award, 2012

USAID Champions of TB Control Award (for CREATE), 2014

Tuberculosis, HIV, Infectious Diseases

  • Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection.  N Engl J Med. 2011;365:2155-66.

  •  

    Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE.  New regimens to prevent tuberculosis in adults with HIV infection.  N Engl J Med 2011;365:11-20. PMCID: PMC3407678

     

  •  

    Dowdy DW, Golub JE, Chaisson RE, Saraceni V. Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics.  Proc Natl Acad Sci U S A. 2012;109:9557-62

     

  •  

    Durovni B, Saraceni V, Moulton LM, Pacheco AG, Cavalcante SC, King BS, Cohn S, Efron A, Chaisson RE, Golub JE.  Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis. 2013;10:852-8

     

  • Churchyard GJ, Fielding KL, Lewis JJ, Coetzee, Corbett EL, Godfrey-Faussett P, Hayes RJ, Chaisson RE, Grant AD. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med,2014;370:301-10. PMC in process.